Jane Street
ZNTL icon

Jane Street’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jane Street’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
490,339
+17,164
+4% +$44.3K ﹤0.01% 6217
2025
Q4 		$639K Sell
473,175
-172,448
-27% -$251K ﹤0.01% 7150
2025
Q3 		$975K Sell
645,623
-18,438
-3% -$27.6K ﹤0.01% 6359
2025
Q2 		$770K Buy
664,061
+515,257
+346% +$680K ﹤0.01% 6097
2025
Q1 		$237K Sell
148,804
-174,710
-54% -$377K ﹤0.01% 8197
2024
Q4 		$980K Buy
323,514
+162,321
+101% +$532K ﹤0.01% 5433
2024
Q3 		$593K Sell
161,193
-11,796
-7% -$42.9K ﹤0.01% 6896
2024
Q2 		$708K Buy
172,989
+48,702
+39% +$544K ﹤0.01% 6434
2024
Q1 		$1.96M Buy
124,287
+78,278
+170% +$1.08M ﹤0.01% 4163
2023
Q4 		$697K Buy
46,009
+6,732
+17% +$98.2K ﹤0.01% 6205
2023
Q3 		$788K Buy
39,277
+14,857
+61% +$377K ﹤0.01% 5541
2023
Q2 		$689K Buy
24,420
+4,398
+22% +$106K ﹤0.01% 5809
2023
Q1 		$344K Buy
20,022
+9,783
+96% +$198K ﹤0.01% 6953
2022
Q4 		$206K Sell
10,239
-32,167
-76% -$692K ﹤0.01% 7634
2022
Q3 		$919K Buy
42,406
+32,936
+348% +$901K ﹤0.01% 5557
2022
Q2 		$266K Buy
+9,470
New +$251K ﹤0.01% 7795
2022
Q1 		– Sell
-5,289
Closed -$285K – 11133
2021
Q4 		$445K Buy
+5,289
New +$409K ﹤0.01% 7469
2021
Q1 		– Sell
-18,876
Closed -$980K – 9666
2020
Q4 		$980K Buy
+18,876
New +$851K ﹤0.01% 4683
2020
Q3 		– Sell
-12,994
Closed -$624K – 8056
2020
Q2 		$624K Buy
+12,994
New +$498K ﹤0.01% 4734

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Jane Street's ZNTL Position: Q1 2026 in Review

Jane Street increased its Zentalis Pharmaceuticals (ZNTL) stake by 3.6% in Q1 2026, buying an estimated $44.3K and bringing the position to 490,339 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #6217.

Jane Street first reported a position in ZNTL in Q2 2020 and has held it in 19 quarters since. The position peaked at $1.96M in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Jane Street held 490,339 shares of Zentalis Pharmaceuticals worth $1.15M as of Q1 2026.
  • Jane Street bought 17,164 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $44.3K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6217 holding.
  • Jane Street first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • Jane Street's Zentalis Pharmaceuticals position peaked at $1.96M in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.